These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase. Choi J; Park SJ; Jee JG Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630 [TBL] [Abstract][Full Text] [Related]
9. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620 [TBL] [Abstract][Full Text] [Related]
10. Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. Flipo M; Willand N; Lecat-Guillet N; Hounsou C; Desroses M; Leroux F; Lens Z; Villeret V; Wohlkönig A; Wintjens R; Christophe T; Kyoung Jeon H; Locht C; Brodin P; Baulard AR; Déprez B J Med Chem; 2012 Jul; 55(14):6391-402. PubMed ID: 22738293 [TBL] [Abstract][Full Text] [Related]
12. Reversion of antibiotic resistance in Blondiaux N; Moune M; Desroses M; Frita R; Flipo M; Mathys V; Soetaert K; Kiass M; Delorme V; Djaout K; Trebosc V; Kemmer C; Wintjens R; Wohlkönig A; Antoine R; Huot L; Hot D; Coscolla M; Feldmann J; Gagneux S; Locht C; Brodin P; Gitzinger M; Déprez B; Willand N; Baulard AR Science; 2017 Mar; 355(6330):1206-1211. PubMed ID: 28302858 [TBL] [Abstract][Full Text] [Related]
13. Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites. Laborde J; Deraeve C; Duhayon C; Pratviel G; Bernardes-Génisson V Org Biomol Chem; 2016 Sep; 14(37):8848-8858. PubMed ID: 27714216 [TBL] [Abstract][Full Text] [Related]
14. New ethionamide boosters and EthR2: structural and energetic analysis. Vianna JF; Bezerra KS; Lima Costa AH; Barbosa ED; Lima Neto JX; Oliveira JIN; Freire VN; Fulco UL Phys Chem Chem Phys; 2021 Oct; 23(40):23233-23241. PubMed ID: 34623361 [TBL] [Abstract][Full Text] [Related]
15. The small-molecule SMARt751 reverses Flipo M; Frita R; Bourotte M; Martínez-Martínez MS; Boesche M; Boyle GW; Derimanov G; Drewes G; Gamallo P; Ghidelli-Disse S; Gresham S; Jiménez E; de Mercado J; Pérez-Herrán E; Porras-De Francisco E; Rullas J; Casado P; Leroux F; Piveteau C; Kiass M; Mathys V; Soetaert K; Megalizzi V; Tanina A; Wintjens R; Antoine R; Brodin P; Delorme V; Moune M; Djaout K; Slupek S; Kemmer C; Gitzinger M; Ballell L; Mendoza-Losana A; Lociuro S; Deprez B; Barros-Aguirre D; Remuiñán MJ; Willand N; Baulard AR Sci Transl Med; 2022 May; 14(643):eaaz6280. PubMed ID: 35507672 [TBL] [Abstract][Full Text] [Related]
16. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. Nikiforov PO; Surade S; Blaszczyk M; Delorme V; Brodin P; Baulard AR; Blundell TL; Abell C Org Biomol Chem; 2016 Feb; 14(7):2318-26. PubMed ID: 26806381 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and molecular docking studies of imidazole and benzimidazole linked ethionamide derivatives as inhibitors of InhA and antituberculosis agents. Raghu MS; Pradeep Kumar CB; Yogesh Kumar K; Prashanth MK; Alshahrani MY; Ahmad I; Jain R Bioorg Med Chem Lett; 2022 Mar; 60():128604. PubMed ID: 35123004 [TBL] [Abstract][Full Text] [Related]
18. Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis. Hicks ND; Carey AF; Yang J; Zhao Y; Fortune SM mBio; 2019 Apr; 10(2):. PubMed ID: 31015328 [TBL] [Abstract][Full Text] [Related]
19. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. DeBarber AE; Mdluli K; Bosman M; Bekker LG; Barry CE Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9677-82. PubMed ID: 10944230 [TBL] [Abstract][Full Text] [Related]
20. Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2. Wohlkönig A; Remaut H; Moune M; Tanina A; Meyer F; Desroses M; Steyaert J; Willand N; Baulard AR; Wintjens R Biochem Biophys Res Commun; 2017 May; 487(2):403-408. PubMed ID: 28416386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]